GlassScriptPhysician profile
Navakanth Gorrepati
NPI 1346455599
$5,229.82
in general payments reported to CMS, 2019-2025
29 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.84 · 2020: $173 · 2022: $587 · 2023: $1,654 · 2024: $1,545 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,591 · Travel and Lodging: $1,785 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.79 |
| Travel and Lodging | $1,785.49 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,184.28 | 2022-2025 | Exalt Model D, Resolution 360 Clip, General - Metal Stents - G.I. |
| Ovesco Endoscopy USA, INC. | $923.56 | 2023 | |
| Abbvie INC. | $774.27 | 2019-2025 | |
| Gilead Sciences, INC. | $201.84 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.52 | 2019-2025 | Xifaxan |
| Celgene Corporation | $163.62 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $80.89 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $66.73 | 2019-2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $65.49 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $62.89 | 2022-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $62.19 | 2023 | |
| Aimmune Therapeutics, INC. | $50.10 | 2024-2025 | Zenpep |
| Shionogi INC | $44.79 | 2020 | |
| Pfizer INC. | $44.08 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.96 | 2025 | Entyvio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $32.82 | 2022-2023 | Andexxa |
| Erbe USA INC | $30.00 | 2020 | |
| Ambu INC. | $26.06 | 2020 | |
| Daiichi Sankyo INC. | $25.71 | 2022 | |
| Phathom Pharmaceuticals, INC. | $24.80 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $24.58 | 2025 | Omvoh |
| Alcresta Therapeutics, INC. | $21.74 | 2024 | Relizorb |
| Recordati_rare_diseases_inc. | $20.27 | 2025 | Panhematin |
| Redhill Biopharma INC. | $19.58 | 2022 | |
| Dynavax Technologies Corporation | $19.35 | 2023 | Heplisav-B |
| Endogastric Solutions, INC | $16.83 | 2022 | |
| Vivus LLC | $15.88 | 2023 | Qsymia |
| Evoke Pharma, INC. | $12.80 | 2023 | Gimoti |
| Apollo Endosurgery US INC | $6.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navakanth Gorrepati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.